Remix Therapeutics Closes $60 Million Financing To Advance Rem-422, Pipeline Of Small Molecule Therapies Designed To Reprogram Rna Processing To Treat Disease
Jan 03, 2024•over 1 year ago
Amount Raised
$60 Million
Investors
Willett AdvisorsWtt InvestmentSurveyorCasdin CapitalArch Venture PartnersAlexandria Venture InvestmentsForesite CapitalAtlas VentureThe Column Group
Description
Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the close of a $60 million financing led by The Column Group. The financing includes participation from existing investors Atlas Venture, Foresite Capital, Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, and Surveyor (a Citadel company) along with new investors WTT Investment, Willett Advisors, and others. The funds will support clinical development of the company's lead program, REM-422, and further advancement of a pipeline of RNA processing targeted therapeutics.
Funding Insights
Based on industry dataVC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech